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Abstract.
Background: Combining PET amyloid- (A) and tau imaging may be critical for tracking disease progression in
Alzheimer’s disease (AD).
Objective:We sought to characterize the relationship between A and tau ligands as well as with other measures of pathology.
Methods: We conducted a multi-center observational study in early AD (MMSE > 20) participants aged 50 to 85 y. The
schedule included cognitive assessments (ADAS-Cog) and CSF measurement of A and tau at baseline and 6 months;
PET-CT imaging with A ([18F]AV45) and tau ([18F]AV1451) ligands at baseline.
Results: 22 participants took part in the study with 20 completing its 6-month duration and 12 having both tau and amyloid
PET. The PET biomarker analysis revealed a strong negative correlation between age and tau in multiple regions. Entorhinal
cortex tau and age interacted significantly in terms of cognitive change over 6 months which may have been to older participants
deteriorating faster despite lower levels of cortical tau. Cortical A associated with entorhinal cortex tau while CSF tau/A
ratio correlated strongly with cortical tau but not A.
∗Correspondence to: Dr. Ivan Koychev, Translational Neuro-
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Conclusion: The negative relationship between age and cortical tau whereby younger patients with mild AD had relatively
greater tau burden is potentially important. It suggests that younger-age onset AD may be primarily driven by tau pathology
while AD developing later may depend on a multitude of pathological mechanisms. These data also suggest that PET-tau
performs better than PET-amyloid in predicting the best validated AD diagnostic marker—the CSF total tau/A ratio.
Keywords: Alzheimer’s disease, amyloid beta-peptides, cerebrospinal fluid proteins, positron emission tomography,
tau proteins
INTRODUCTION
The advent of positron emission tomography
(PET) amyloid- (A) tracers [1] has made it possi-
ble to detect A plaque load in vivo. The utility of A
PET is that A burden predicts progression of mild
cognitive impairment (MCI) to Alzheimer’s disease
(AD) [2–4] and allows proof of amyloid pathology
for the purposes of enrolling patients into AD clini-
cal trials [5, 6]. However, A burden is a relatively
poor correlate of disease progression in established
AD: in vivo PET measures correlate poorly with
symptom severity [7–10], and its spatial distribution
differs from the pattern of cortical atrophy and glu-
cose hypometabolism [7, 8, 11, 12].
Until recently the only practical method of mea-
suring tau pathology in vivo has been through CSF
sampling [13, 14], which does not allow differenti-
ation between aggregated tau pathology such as in
AD and non-specific neurotoxicity. Recent advances
however have led to the development of tau lig-
ands for PET imaging [15, 16], which now enables
localization of tau pathology in brain in life. One
tracer, [18F]AV1451 (formerly called [18F]T807), has
a binding pattern that follows closely NFTs in post-
mortem studies [17, 18]. The binding of the tracer is
highly specific to tau relative to A in vitro [17, 18]
and has a differential uptake in AD patients relative
to controls [19] and other tauopathies [20, 21]. Cru-
cially, tau pathology measured with [18F]-AV1451
co-localizes with hypometabolism measured with
FDG-PET [22] and is potentially useful for tracking
disease progression and staging [23, 24].
In this study, we sought to clarify, early in the
symptomatic phase, the relationship between the
tau-selective PET tracer [18F]AV1451 and the more
established measures of AD pathology: A PET
(using [18F]AV45 - florbetapir), CSF tau/p-tau, and
A, as well as cognitive performance. We recruited
patients with early AD (Mini-Mental State Exami-
nation (MMSE) > 20) and obtained PET, CSF, and
cognition measures at the study baseline. We repeated
CSF and cognitive measures at 6 months. We hypoth-
esized that in our early AD study group, PET A
would correlate with tau signal in areas affected early
in the disease process and that change in cognitive
impairment over 6 months would be most demonstra-
ble in the subset of patients with greater A and/or
tau loading. In terms of PET/CSF relationship we
expected to replicate the reports of a negative corre-
lation between PET A cortical binding and CSF A
peptide [25, 26] and a positive relationship between
CSF and PET cortical tau measures [27, 28]. Our prin-
cipal aim of this analysis, though, was to determine
which PET measures would best predict the most
informative and currently available AD biomarker
(CSF tau/A ratio).
METHODS
Study design
A non-interventional multi-site study was carried
out at the 6 centers of excellence in the UK that consti-
tute the NIHR Translational Research Collaboration
in Dementia (NIHR Biomedical Research Centers or
Dementia Units associated with the following NHS
Trusts: Oxford University Hospitals (OUH), South
London and Maudsely (SLaM), Cambridge Univer-
sity Hospitals (CUHT), University College Hospital
London (UCLH), West London Mental Health Care
(WLMHC), and Newcastle Hospitals). Through local
memory clinic services, we recruited patients aged
50–85 with a diagnosis of probable AD (with no AD
pathophysiological evidence) according to National
Institute of Aging-Alzheimer’s Association (NIA-
AA) criteria [29]. Other inclusion criteria were i)
MMSE score of 20 and above, ii) Modified Rosen-
Hachinski Ischemic score of 4 or less, iii) being on
stable medication dose for any non-significant medi-
cal conditions for at least one month; iv) stable dose
for at least 3 months if treated with cholinesterase
inhibitors and/or memantine.
We aimed to enroll 24 patients across all sites. Par-
ticipants attended a screening visit where consent was
obtained and eligibility assessed. This was followed
by a baseline visit within 30 days, with three further
assessments assessment episodes over a six-month
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period (baseline, month 1, month 3 and month 6).
Due to the demanding nature of the first and last vis-
its, study procedures were completed over a period of
up to 5 days. The original purpose of this study was
to evaluate the acceptability and feasibility of such
in-depth and high frequency biomarker sampling in
view of organizing a larger study following a similar
design.
The full study schedule will be reported elsewhere
but included demographic, clinical, and physical
exam together with MMSE and assessment of sensory
and motor impairment, mood and behavior, global
function, and function. Cognition was assessed using
pen and paper tests (Alzheimer’s Disease Assessment
Scale – Cognitive subscale (ADAS-Cog) and MMSE)
as well as computerized methods (Cambridge Neu-
ropsychological Test Automated Battery (CANTAB)
Paired Associates Learning (PAL), and Spatial Work-
ing Memory (SWM)).
At baseline, we performed PET for regional A
and tau load with all imaging being performed at a
single site in London (IMANOVA Ltd). One study
site was too distant for participant travel and so was
not included in the PET component of the trial (New-
castle). The protocol included a T1-weighted MRI
structural scan and two dynamic PET scans, one with
[18F]AV45 (0–60 min, 150 ± 24 MBq) and one with
[18F]AV1451 (0–120 min, 163 ± 10 MBq) to mea-
sure A and tau respectively. The MRI scan was made
on a Siemens 3T Tim Trio with a 32-channel phased
array head coil. A 1 mm isotropic whole-brain struc-
tural 3D T1-weighted MPRAGE was acquired using
TI = 880 ms, TR = 2000 ms and FA = 8° with a par-
allel imaging factor of 2 in 4 m: 54 s. For the PET
scans, subjects were positioned in the PET scanner,
after the insertion of a venous cannula in an antecu-
bital or forearm vein, and a head-fixation device was
used to minimize head movement during data acqui-
sition. The PET scans were acquired on two Siemens
PET/CT scanners (Hi-Rez Biograph 6 and Biograph
6 TruePoint with TrueV, Siemens Healthcare, Erlan-
gen, Germany) while for each subject, A and tau
PET scans were acquired on the same scanner. A
low-dose CT scan was performed immediately before
each PET scan in order to estimate attenuation. A
single intravenous bolus of [18F]AV45 (Florbetapir)
tracer (150 ± 24MBq) for a 60 min A PET scan
and [18F]AV1451 ([18F] T807) tracer (163 ± 10MBq)
for a 120 min tau scan was injected to each subject.
The dynamic images were reconstructed using a 2D
Filtered Back Projection (FBP) algorithm resulting
in a 128 × 128 matrix with 2 mm isotropic voxels.
Corrections were applied for attenuation, randoms,
scatter, and tracer radioactive decay. All image pro-
cessing and analysis was performed in MIAKAT™
(www.miakat.org). Dynamic PET data were cor-
rected for motion and a neuroanatomical atlas [30]
was nonlinearly registered to each subject using the
individuals T1 MRI scan to enable parcellation of
regions of interest. Regional standard uptake val-
ues (SUVr) with respect to cerebellar gray matter
were obtained for the 30–60 min time window for
[18F]AV45 and 60–120 min for [18F]AV1451 (one
participant stayed in the scanner for 110 min only –
we used 60–110 min time window in that instance)
to investigate static outcome measures. For both tau
and A measures regions of interest were identi-
fied on the basis of the Braak and Braak staging
model of AD [31] – entorhinal cortex (represented
by gyrus ambiens) and hippocampus (stages 1-2);
parahippocampus, fusiform gyrus, posterior cingu-
late, inferior temporal gyrus, thalamus, and amygdala
(stage 3-4); frontal, parietal as well superior tem-
poral and medial temporal cortices (stage 5-6). We
also extracted overall cortical SUVr values (cortex
defined as occipital, insular, temporal, frontal, cin-
gulate, and parietal cortices) for both A and tau
ligands.
Cerebrospinal fluid (CSF) was collected at
the baseline visit and 6-month follow-up. Total
tau (t-tau), phosphorylated tau (p-tau) and A
(i.e., A42) concentrations were measured using
INNOTEST enzyme-linked immunosorbent assays
(ELISAs) (Fujirebio Europe N.V., Gent, Belgium).
Well-established standard operating protocols for
sample collection and management were used [32]
and assays performed according to manufacturer’s
instructions, as previously described in detail [33].
All measurements were performed by board-certified
laboratory technicians who were blinded to clini-
cal data. The measurements were performed on one
occasion using one batch of reagents. Intra-assay
coefficients of variation were below 10% and all
samples measured in the quantitative range of the
assays.
Statistical analysis
SPSS (Version 22) and the RStudio statistical pack-
age (Version 0.99.896) were used to analyze the
data. The relationship between A and tau in the
regions of interest and cortex were compared using
two-way Pearson’s correlations. We followed up any
significant relationships with linear models including
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age as a covariate to investigate its potential effects.
The relationship between A/tau SUVr values and
age was also explored using two-way Pearson’s
correlations.
In terms of cognitive measures analyses, we used
repeated measures analyses of variance (ANOVAs)
on memory-based tasks where longitudinal measure-
ments were available (ADAS-Cog, PAL, SWM) to
determine whether there was a significant change to
cognition over the 6-month study period. Within sub-
ject factor for each model was study visit (baseline,
month 1, month 3, and month 6 for PAL and SWM;
baseline and month 6 for ADAS-Cog) and outcome
variables were respectively: ADAS-Cog total score,
PAL total projected errors and SWM between search
errors. Sex was selected as between-subject factor for
the three models while age was evaluated as a covari-
ate. We explored the effect of PET tau and A SUVr
levels on baseline and longitudinal cognition (cal-
culated by subtracting baseline cognitive score from
6-month score for cognitive variable) using linear
models. We repeated these analyses with entorhinal
cortex tau (due to a significant correlation we found
between cortical A and entorhinal tau, see results
section) and posterior cingulate A (due to reports of
posterior cingulate A predicting cognitive progres-
sion [3]) as independent variables. Only ADAS-Cog
scores were included in these analyses as SWM and
PAL mean error variables were not normally dis-
tributed in the sample of patients who underwent
PET.
We analyzed CSF concentrations for A, tau, p-
tau, and also generated tau/A ratios. We performed
two-way Pearson’s correlations between selected
SUVr values (cortical tau and A) and the four CSF
measures at baseline visit (A, tau, p-tau, and tau/A
ratio). To test the hypothesis that either cortical A or
tau may predict CSF change over the 6-month study
period we ran linear models with cortical A and
tau as independent variables and CSF measures (tau,
p-tau, A, and tau/A) as repeated dependent vari-
ables (baseline and 6-month follow-up). Finally, we
explored the CSF markers’ association with longi-
tudinal cognition by performing linear models with
baseline (i.e., visit 1) CSF tau, p-tau, A, and tau/A
ratio as independent variables and ADAS-Cog and
PAL score change over 6 months (i.e., baseline scores
subtracted from 6-month scores) as dependent vari-
ables (SWM scores were not included as they were
not normally distributed in the subsample of patients
who had baseline CSF). We tested the moderating
effect of age in these models.
Ethics
The study was approved by a National Research
Ethics Committee London on the 19th of Sept. 2014
– IRAS reference 14/LO/1467, IRAS project ID:
156309. All participants had mental capacity for
informed consent.
RESULTS
Recruitment
Eight participants were excluded at screening: 5
because they failed to meet study entry criteria, one
because of having had a recent PET scan, one for
withdrawal of consent, and one for an unspecified
reason. Twenty-two participants were included after
screening and 20 remained at follow-up (one drop-
out due to consent withdrawal and one exclusion
due to psychosis). All 20 participants completed
the cognitive assessments as planned (CANTAB and
paper-based tests). Out of the 20 participants, 16 had
CSF testing at baseline (2 did not complete due to
medical reasons and 2 due to logistical reasons). At
follow-up CSF was taken from 16 participants – rea-
sons for not doing the testing were again medical (2)
and logistical (2) but this was the case for three peo-
ple who had completed the baseline CSF (i.e., three
participants who had follow-up CSF did not have
baseline CSF). Therefore 13 participants had CSF
testing both at baseline and follow-up. We planned
to perform PET imaging at five out of the six study
centers and 15 of the 16 eligible study completers
underwent imaging (one missing imaging because of
logistical reasons). PET A data with [18F]AV45 was
successfully obtained for 14 out of 15 participants
(1 participant had unusable data due to excessive
motion) and PET tau data with [18F]AV1451 for 12
of the 15 participants (3 participants did not complete
at least 70 min of image acquisition).
See Table 1 for demographics of patients included
in the study.
PET tracer analyses
Our regional correlation analysis (12 participants
included) revealed that cortical A was associated
with tau in the entorhinal cortex (r = 0.6, p = 0.04,
Fig. 2A), thalamus (r = 0.72, p < 0.01) and parahip-
pocampus (r = 0.63, p = 0.03). This relationship was
not moderated by age; see Fig. 1 for a topographical
representation of tau and A binding in individual
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Table 1
Demographics
Demographics Mean SD
Sex 11M 9F
Age 71.3 8.4
Education (y) 14.7 3.9
Premorbid IQ 116.0 8.2
MMSE 24.8 2.4
ADAS-Cog 14.6 6.1
Rosen-Hachinski score 0.7 0.9
Clinical Dementia Rating score 0.63 0.27
Geriatric Depression Scale 2.2 1.34
Bristol Activities of Daily Living Scale 3.2 3.0
participants. Age correlated negatively with cortical
(r = –0.83, p < 0.01, or= –0.02, p < 0.001) as well as
regional tau load across Braak stage regions: entorhi-
nal cortex non-significant at trend (r = –0.56, p = 0.06,
Fig. 2B), hippocampus (r = –0.62, p = 0.03), occipital
(r = –0.77, p < 0.01) parietal (r = –0.90, p < 0.001) and
frontal cortices (r = –0.60, p = 0.04). There was no
statistically significant relationship between cortical
A SUVr values and age.
Cognitive test results
Twenty participants completed serial pen and
paper (ADAS-Cog at baseline and month 6) and
computerized cognitive measures (PAL and SWM
CANTAB tests at baseline, month 1, month 3 and
month 6). Unsurprisingly, in this mildly demented
group, no model showed significant change in
cognition.
We proceeded to explore the relationship between
ADAS-Cog scores (baseline cross-sectional and over
time) and cortical tau, entorhinal tau, and cortical A
posterior cingulate SUVr values for the 12 partici-
pants who underwent both tau and amyloid PET that
was done at baseline. In terms of the baseline cross-
sectional ADAS-Cog models, there were no main
effects of any of the four PET variables, and these
models were not modulated by age. In the longitu-
dinal ADAS-Cog models (i.e., baseline ADAS-Cog
scores subtracted from 6-month scores) entorhinal
tau loading did not exert a main effect (= –1.4, CI
[–19.4, 16.6], p = 0.9), but its interaction with age
Fig. 1. Topographical plots of PET SUVr levels for the 12 participants who underwent both A and tau imaging. A and B demonstrate,
respectively, [18F]AV45 (A) and [18F]AV1451 (tau) topographical distribution of SUVr signal across the 12 participants (each column
represents a participant; participants have been ordered according to baseline MMSE scores).
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Fig. 2. PET tau and A scatterplots: A) Cortical A (vertical axis) and entorhinal tau (horizontal axis) scatterplot. B) Age (vertical axis)
and entorhinal (horizontal axis) tau scatterplot. C) Illustration of the interaction between age and entorhinal tau on cognitive progression.
ADAS-Cog score change from baseline to 6-month follow-up on the vertical axis, entorhinal tau on the horizontal axis. Scatterplot is split
with left side featuring those under the median age (72.5 y) and the right with those above it. D) ADAS-Cog score change from baseline to
6-month follow-up (vertical axis) and cortical A (horizontal axis).
was statistically significant (= 0.3, CI [–0.04, 0.61],
p = 0.03). This was due to older patients being dis-
proportionately affected by tau loading (see Fig. 2C).
Cortical tau did not exert a main effect in the ADAS-
Cog longitudinal model, and this was not modulated
by age. Both cortical and posterior cingulate A
SUVr levels did not reach significance in respect to
the cognitive progression model (Fig. 2D). Age and
period since symptom onset did not interact signifi-
cantly with PET A values in these models.
CSF analyses
CSF was collected from 16 patients at baseline and
from 16 patients at follow-up (13 patients had both
baseline and follow-up CSF collection). We found
that cortical tau correlated strongly with baseline CSF
tau (r = 0.80, p < 0.01), p-tau (r = 0.70, p = 0.02) as
well as tau/A ratio (r = 0.73, p = 0.02; Fig. 3) but
not A. Cortical A did not correlate with baseline
CSF measures (tau, p-tau, A, or tau/A).
In the linear models exploring whether cortical A
or tau predict CSF change over the 6-month study
period, we found that neither cortical tau nor Awere
statistically significant in predicting change in tau,
p-tau, A, or tau/A over the 6-month period.
To test the hypothesis that CSF markers at baseline
predict cognitive decline, we analyzed the relation-
ship between four CSF variables (baseline CSF tau,
p-tau, A, and tau/A ratio) to longitudinal cognitive
change (ADAS-Cog and PAL tests). Baseline CSF
tau, p-tau, and A exerted significant main effects in
the ADAS-Cog longitudinal model: tau (= 0.0095,
CI [2.33 0.018]p < 0.05), p-tau (= 0.0974, CI [0.002
0.192] p < 0.05), and A (= 0.0492, CI [0.004
0.081] p = 0.03). Tau but not A interacted with age in
these models (= 0.004, CI [4.199 0.001] p < 0.05);
the interaction in the p-tau model did not reach signif-
icance. There was no main effect of baseline tau/A
ratio on the ADAS-Cog longitudinal model. There
were no main effects of baseline tau, p-tau, A, or
tau/A ratio in the PAL longitudinal models.
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Fig. 3. CSF tau/A relationship with PET cortical tau (A) and A (B). On the vertical axes are CSF tau/A ratios and on the horizontal axes
are cortical tau (A) and cortical A (B). Visit 1 and Visit 2 CSF measurements in dark gray rombes and light gray rectangles respectively.
PET scanning was done at baseline only.
DISCUSSION
In this study of people diagnosed with mild AD, we
explored the relationships between the recently devel-
oped PET tau tracer, [18F]AV1451, and established
AD research measures: PET A ([18F]AV45), CSF
measures of tau and A and cognitive measures. We
found a relationship between tau and age, whereby
younger patients with mild AD had relatively greater
tau burden in the entorhinal cortex. Entorhinal cortex
was also the only region where PET measures of tau
associated with cortical A binding. The relationship
between tau and age was underscored by the finding
that cognitive deterioration over the 6-month period
was associated with tau levels in the entorhinal cor-
tex especially in older participants. Finally, cortical
tau correlated strongly with CSF tau measures but
there was no relationship between A PET and CSF
measures.
Age effects
The finding of a negative relationship between age
and tau deposition appears at odds with evidence for
rising MTL tau levels with age [23] but may be reflec-
tive of different rates of tau accumulation depending
on age of illness onset. A recent tau PET study pro-
vided evidence in support of this by showing that
while in unimpaired people tau deposition in MTL
correlates with age, tau propagation in MCI extends
beyond MTL (i.e., inferotemporal and fusiform gyri)
in younger and more cognitively impaired individuals
[34]. This is consistent with studies showing that in
late-onset AD the medial temporal lobes are prefer-
entially affected while younger onset disease features
greater cortical degeneration and relative sparing of
the hippocampus [8, 35–38].
The age effects observed here may reflect the view
that that AD features distinct clinico-pathological
phenotypes: a typical, late-onset form affecting pref-
erentially the medial temporal lobe and atypical,
younger-onset forms that affect the whole cortex [39].
These younger-onset forms are less dependent on
APOE4 risk factors, progress quicker and have a more
varied clinical presentation [40, 41]. This form of
AD may be a primarily tau-driven disease as in the
current study as well as in others there was no rela-
tionship between A and age [8]. The relationship
we see between age and tau pathology suggests a
continuum of disease between young-onset and late-
onset disease with the younger group in the present
study with an onset in their mid-60 s sharing some of
characteristics of young-onset dementia, more usu-
ally considered a disorder with an onset before the
age of 60.
Effects of tau and Aβ on change in cognition
Overall, there was no significant deterioration of
cognition in our group over the 6-month period,
as expected in this very mild group where longer
periods are required to observe disease progression.
Nonetheless, we found both PET and CSF measures
of tau but not amyloid pathology were associated
with worsening cognition at 6 months. In the PET
models, this association between tau and cognition
appeared to be driven primarily by older participants
as entorhinal tau levels in the group older than the
mean 72.5 y were positively related to cognitive pro-
gression, while there was no such relationship in
the younger group. The interacting effect of age and
tau accumulation on cognitive progression was repli-
cated in the CSF tau models. That tau correlates better
with clinical features of dementia than A pathology
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is in line with other early studies using PET imaging
of tau pathology, showing that Braak staging (esti-
mated automatically on the basis of spatial pattern
of tau accumulation) correlates with extent of base-
line [23, 24] and longitudinal [23] cognitive deficits.
We interpret our finding of interaction between tau
measures and age on cognition as a suggestion that
tau accumulation in the MTL structures such as the
entorhinal cortex has a disproportionately negative
effect on cognition in older age, i.e., in older people
relatively lower levels of tau in the entorhinal cor-
tex are associated with cognitive deterioration. These
effects may be due to the lower cognitive reserve in
older people or to other pathology contributing to
dementia in this age group.
Relationship between CSF and PET biomarkers
Finally, we compared tau and A PET signal with
the best validated marker of AD pathology—tau/A
CSF ratio [42]. We found that it was baseline cortical
tau but not A that associated with the tau/A ratio.
This relationship was due to a correlation between
cortical and CSF measures of tau which is in line
with the two published studies comparing CSF and
PET tau [27, 43]. These results suggest that tau is
more closely aligned with pathological processes at
the stage of developed illness. This could be due
to amyloid reaching a plateau around the time of
symptom onset as has been suggested previously
[44].
An important difference from existing literature
was the lack of a significant negative relationship
between cortical A as measured with PET and CSF
A [25, 45]. Most studies examining this relationship
included both amyloid-positive and amyloid-negative
individuals; within either group the correlations are
weaker or absent [46]. Our group was relatively
homogeneous in terms of PET amyloid signal and
therefore the most likely explanation for the negative
result was the modest sample size of our cohort and
so should be treated with caution.
We also explored the relationship between PET
cortical A signal and tau ligand binding in the dif-
ferent regions used for Braak staging. We found that
only entorhinal tau correlated with cortical amyloid.
This finding could be interpreted as supportive for
the ‘trigger and bullet’ hypothesis of the interac-
tion between A and tau in AD pathophysiology
[47]—that a critical level of A burden needs to be
reached before that toxic tau cascade is triggered
starting from the entorhinal cortex. However, the
existing evidence suggests that tau accumulation in
the MTL is part of normal aging with tau propagat-
ing beyond MTL only in those who are classed as A
positive [23].
Strengths and limitations
This is a study with notable strengths and weak-
nesses. In terms of strengths, it is one of the few
studies to report not only both A and tau imaging
but also CSF markers of A and tau pathology, and
with all measures being conducted within a very short
time period. A further strength is the longitudinal (6
month) data on cognition and CSF AD biomarkers.
Last but not least, it demonstrated the feasibility of a
multicenter, in-depth and high frequency biomarker
sampling design which may be crucial for identify-
ing temporal trends in AD biomarker evolution and
clinical trials design. In terms of limitations, firstly
the study was designed to assess the feasibility and
acceptability of the in-depth and frequent biomarker
investigations and therefore was not powered for mild
to moderate effects sizes. As a result, most of the
results should be treated with caution – for instance
the lack of replication of a negative relationship
between CSF A and tau may be a Type II error on
account of the small sample size. Secondly, the study
likely suffers from a recruitment bias; the sample con-
sisted of 2–4 patients per site who for the purposes
of quick study completion were highly motivated and
known to the study investigators and so may not be
representative of a randomly selected mild AD group.
Thirdly, the study included a modest in length follow-
up (6 months), which is likely to be insufficient to
answer questions about the longitudinal relationship
of AD biomarkers in the mild stages of the disease.
Lastly, this study did not include a control group
which precluded the possibility for assessing pro-
gression data against normative data. We are now
in the process of attempting to address the multi-
tude of limitations by setting up a large, multi-site
study informed by the acceptability and feasibility
currently reported study. In terms of PET methodol-
ogy, tau tracers are still early in their development
and further developments are needed to clarify their
reliability and specificity. We note that [18F]AV-1451
used in this study has off-target binding of relevance
on some neurodegenerative disorders [17], although
neuromelanin has been ruled out as a significant
determinant of binding in AD [21], and the cortical
distribution is unlikely to be explained by monoamine
oxidase.
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Conclusion
In this study, we found a significant relationship
between age and cortical PET tau whereby younger
patients with similar severity of clinical disease have
disproportionally more tau pathology. These results
argue that younger age onset AD may be primarily
driven by tau pathology while AD developing later
in life may be driven by a multitude of pathologi-
cal mechanisms. Nonetheless, cortical A correlated
with tau in the entorhinal cortex, the origin of AD
pathology which suggests that irrespective of age,
AD is a disorder triggered by A deposition and
progressed through tau pathology. Critically, in the
stage of developed illness cortical tau is a better cor-
relate than A of the best validated AD diagnostic
marker—the CSF tau/A ratio. The results of this
study remain to be replicated in larger samples.
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